Importantly, the extent of tumor-cell killing by a combination of UniCAR 5B9.28.z NK-92 cells and the ErbB2-specific TM 5FE was equivalent to that of clinical-grade NK-92/5.28.z cells that carry a classical ErbB2-specific CAR with CD28 and CD3ζ domains and are currently under evaluation in a phase I clinical trial in glioblastoma patients (clinicaltrials.gov; NCT03383978) [30, 34]. This evidence concerns the gene ERBB2 and glioblastoma.